Clinical Trial Update: Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

View source ↗

Summary

TAR-200 has been approved for marketing for non-muscle invasive bladder cancer, and the update notes a pre-approval expanded-access program for treating physici…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• TAR-200

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Non-Muscle Invasive Bladder Neoplasms | Status: APPROVED_FOR_MARKETING